First-line immunotherapy combination fails to improve OS in lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

First line immunotherapy with Imfinzi (durvalumab) or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login